Breaking News on Global Pharmaceutical Technology & Manufacturing

Hot Topics > Lifecycle management

News in brief

Dong-A and Meiji Seika to build biosimilars plant


South Korean drugmaker Dong-A and Japan’s Meiji Seika Pharma will build a biosimilars plant in a bid to target the global Ab-based drug market.

The new 145,200sqm facility in Songdo, South Korea and will house R&D units in addition to manufacturing suites.

Dong-A said the facility will focus on the development of three biosimilar drug products, one of which will be a version of the breast cancer treatment Herceptin, tries of which are scheduled to begin later this year.

Dong-A also plans additional investment in Songdo to export biopharmaceutical products such as PEG-G-CSF for neutropenia, interferon beta, and diabetes treatments in Dong-A's current pipeline.

The firms are also seeking to establish a joint-venture entity to oversee operations at the site when construction is completed in 2014, although this is still under discussion.

Key Industry Events


Access all events listing

Our events, Events from partners...